CTOs on the Move

ALung Technologies

www.alung.com

 
ALung Technologies has developed the Hemolung Respiratory Assist System (RAS), a dialysis-like alternative or supplement to mechanical ventilation. The Hemolung RAS provides Respiratory Dialysis,a simple, less invasive form of extracorporeal CO2 removal. By removing carbon dioxide and delivering oxygen directly to the blood, the Hemolung RAS allows the patients lungs to rest and heal. Applications of the device include preventing intubation in acute exacerbation of chronic obstructive pulmonary disease (COPD) and enabling ultra-protective ventilation in acute respiratory distress syndrome (ARDS).
  • Number of Employees: 5K-10K
  • Annual Revenue: $1-10 Million
  • www.alung.com
  • 2500 Jane St Ste 1
    Pittsburgh, PA USA 15203
  • Phone: 412.697.3370

Executives

Name Title Contact Details

Funding

ALung Technologies raised $10.53M on 12/04/2015
ALung Technologies raised $36M on 04/12/2017

Similar Companies

Dentamach

Dentamach Incorporated is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AccessOne MedCard

AccessOne is a leading provider of flexible, co-branded patient financing solutions. Founded by providers, our solution provides a consumer-focused experience which drives high patient satisfaction for our clients. We have helped over one million consumers afford out-of-pocket medical expenses for health systems nationwide. We offer the most comprehensive platform in the industry with funding models that help more providers and programs that reach more patients. All patients qualify for our program with no credit reporting or negative outcomes.

OptumHealth

OptumHealth is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Anspach Holdings

The Anspach Effort, Inc. is a successful, continuously evolving business whose focus concentrates on high-speed instrumentation for Neurosurgery, Neurotology, Otology, and Orthopedics. The company is committed to providing product quality, technology,

Miromatrix Medical

The Miromatrix Medical technology has the potential to enable the creation of fully biological replacement organs for the human body. In addition to the Company’s internal efforts focused on the development of its first product – a biological mesh for hernia repair – scientists around the globe are working with the Company’s technology and are taking critical steps toward the creation of human organs including the liver, lung, kidney, pancreas and heart. While our biological mesh development program has been conducted internally, our intent is for current and future products to be developed both at Miromatrix and in partnership with the best among those external groups already working with our technology in order to utilize this pre-existing expertise to develop individual products in the most efficacious, cost-effective and timely way possible.